MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology and Fibrosis New Japanese Patent Further Strengthens Intellectual Property Portfolio Covering Company’s Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Serves as...

MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair,...

NapaJen Pharma Announces First Patient Dosed in Phase 1 First-in-Human Clinical Trial of Novel RNA Interference (RNAi) Therapeutic NJA-730 is an Anti-CD-40 Small Interfering RNA (siRNA) Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease Program Leverages NapaJen’s Immune...

Aphios Granted United States Patent for Improved Delivery of Targeted siRNA Using Nanotechnology WOBURN, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Aphios Corporation today announced that it has been granted United States Patent No. 9,981,238 entitled “Apparatus and Methods for Making Nanosomes...

MDRNA, Inc. Appoints James M. Karis to Its Board of Directors BOTHELL, WA--(Marketwire - August 11, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that James M. Karis has been appointed to the Company's Board of Directors. His appointment brings the number...